BioCentury
ARTICLE | Company News

Allergan, Eli Lilly cancer news

July 20, 2015 7:00 AM UTC

The U.K. Court of Appeal ruled that Allergan’s pemetrexed salt formulations would indirectly infringe an Alimta pemetrexed vitamin dosing regimen patent. The patent covering vitamin dosing regimens of the antifolate that inhibits thymidylate synthase, dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT) expires in June 2021. Lilly said the Court of Appeal also held that there is no difference in the indirect infringement law between the U.K., France, Italy and Spain, thus reversing the English High Court’s declaration of noninfringement over the Alimta patents in those countries (see BioCentury, June 9, 2014). ...